πŸ“Š Biopharmaceutics and Pharmacokinetic
Q. Which of the following is not an objective of bioavailability studies?
  • (A) Primary stages of development of suitable dosage form for new drug
  • (B) Determination of the influence of excipients, patient-related factors, etc
  • (C) Development of new formulations of the existing drugs
  • (D) Control the quantity of the drug to be administered
πŸ’¬ Discuss
βœ… Correct Answer: (D) Control the quantity of the drug to be administered
πŸ“Š Biopharmaceutics and Pharmacokinetic
Q. What is the equation of bioavailable fraction?
  • (A) 1/Bioavailable dose
  • (B) 1/Administered dose
  • (C) Bioavailable dose/Administered dose
  • (D) Administered dose/Bioavailable dose
πŸ’¬ Discuss
βœ… Correct Answer: (C) Bioavailable dose/Administered dose
πŸ“Š Biopharmaceutics and Pharmacokinetic
Q. What is bioavailability?
  • (A) The time of absorption of the drug from its dosage form
  • (B) The rate of absorption of the unchanged drug from its dosage form
  • (C) The time of absorption of the unchanged drug from its dosage form
  • (D) The rate of absorption of the drug from its dosage form
πŸ’¬ Discuss
βœ… Correct Answer: (B) The rate of absorption of the unchanged drug from its dosage form
πŸ“Š Biopharmaceutics and Pharmacokinetic
Q. Bioavailability of drug from topical administration is affected by…..
  • (A) Skin condition
  • (B) Topical vehicle
  • (C) Application condition
  • (D) all of the above
πŸ’¬ Discuss
βœ… Correct Answer: (D) all of the above
πŸ“Š Biopharmaceutics and Pharmacokinetic
Q. USP dissolution test apparatus type-II is also called as…..
  • (A) Hansen paddle type
  • (B) paddle over disc
  • (C) Rotating basket type
  • (D) none of the above
πŸ’¬ Discuss
βœ… Correct Answer: (A) Hansen paddle type